Articles tagged with Drug Resistance
Researchers have identified new ways to target and kill the malaria parasite in human bloodstreams, which could lead to the development of new anti-malarial drugs. The discovery provides a promising avenue for combating the disease, but also highlights the need for continued efforts to address growing resistance to current treatments.
A study found contrasting patterns of malaria drug resistance in human blood and mosquito midgut samples, with pyrimethamine-resistant parasites dominating human blood and cycloguanil-resistant mutants prevalent in mosquitoes.
UCSF researchers have discovered the molecular basis for tamoxifen resistance and found a potential way to defeat it. They showed that cells can develop resistance through epigenetic modification, specifically by elevating expression of the 'survival' gene AKT.
Pediatric oncologists and biochemists advance treatment options for neuroblastoma by studying tumor biology at the molecular level. The study found that certain ALK mutations make cancer cells more resistant to crizotinib, but increasing dosage may overcome this resistance.
Scientists discovered a deadly parasite with duplicated, tripled, and quadrupled chromosomes, defying nature's rule. This bizarre occurrence could be an adaptation to survive harsh environmental stresses, such as drug pressure.
Researchers found that a mushroom compound, verticillin A, improves the efficacy of cancer drugs like TRAIL and etoposide by sensitizing cancer cells to cell death. The compound works by upregulating a gene called BN1P3, which promotes cell death and makes cancer cells more responsive to TRAIL.
A new study reveals that antivirulence drugs can suppress resistance in pathogens by targeting social interactions and cooperation. Laboratory simulations showed that resistant strains will not overtake sensitive strains when therapies target cell-to-cell communication, allowing antivirulence therapies to work even when resistance arises.
Over the past decade, antiretroviral therapy has effectively managed HIV in adults with virological failure to all three original drug classes. Since 2000, nearly one in five patients achieved undetectable viral loads after treatment failure, increasing to nearly three in five by 2009.
Researchers mapped the global spread of drug-resistant influenza, revealing that genetic mutations and human migration through air travel can lead to rapid transmission. The study suggests that a combination of factors, including overuse of antiviral drugs and human movement, contribute to the emergence of resistant strains.
Researchers at Moffitt Cancer Center have developed a monitoring technology that can provide a better understanding of drug resistance in multiple myeloma and assist in individualized patient treatments. The technique uses Liquid Chromatography Multiple Reaction Monitoring (LC-MRM) to quantify biomarkers of human disease.
Researchers have identified the key features in yeast cells that allow them to colonize human tissue, paving the way for new treatments. A new class of medicines and vaccines is being developed to combat drug-resistant fungal infections.
A new study published in Archives of Physical Medicine and Rehabilitation found that higher volume of resistance training combined with aerobic exercise did not yield additional benefits for patients undergoing cardiac rehabilitation. However, the combination of RT and AT resulted in substantial physical fitness benefits and reductions...
A Miriam Hospital study found that male and female smokers who completed a 12-week resistance training regimen were twice as likely to successfully quit compared to those without weight lifting. The study also showed long-lasting effects, with 15% of participants maintaining their quit attempt three months after the study.
Research warns that using powerful antibiotics to treat diseases like MRSA and malaria can accelerate the emergence of resistant strains. The study suggests strategies for slowing resistance spread and preventing mutations.
Researchers at UCLA's Jonsson Comprehensive Cancer Center developed combination treatments to combat BRAF gene mutations in melanoma. The study identified optimal combinations of molecules to block key pathways, showing promise for extending treatment effectiveness and improving patient outcomes.
Researchers found that combining tamoxifen with dasatinib reverses chemo-resistance caused by cancer-associated fibroblasts. The combination normalized glucose intake and reduced mitochondrial oxidative stress, leading to nearly 80% cell death.
Researchers identified a new gonorrhea strain, H041, with extreme resistance to cephalosporin-class antibiotics. This discovery poses a significant threat to public health as the last remaining effective treatments are no longer effective against the bacterium.
A new mathematical model predicts the location of mutations that lead to HIV-drug resistance, providing a potential solution to improve anti-HIV drug design. The study suggests that understanding these physical properties and interactions can help develop better strategies for combating the virus.
A new study found that ivermectin dramatically reduces malaria transmission among people living in Senegalese villages. Ivermectin was administered as part of a campaign to fight onchocerciasis and appeared to kill malaria-carrying mosquitoes, resulting in a 79% decline in mosquitoes carrying Plasmodium falciparum.
A new Cochrane Systematic Review finds that Rapid Diagnostic Tests (RDTs) are highly accurate in detecting malaria parasites, with a success rate of at least 19 out of 20 cases. This development holds promise for improving diagnosis and treatment of malaria in resource-constrained settings.
Researchers have identified specific resistance mutations in the p7 protein that may explain the lack of effectiveness of current p7 inhibitor drugs. The study supports the use of combination therapies inhibiting p7 as a potential component of future HCV-specific treatments, offering new hope for effective therapies.
A new research area seeks to discover ways to manage the evolution of drug-resistant disease organisms and slow their spread. The goal is to develop a science-based model for drug-resistance management that can inform treatment guidelines for various diseases, including malaria, MRSA, AIDS, and cancer.
A phase II clinical trial found PCI-32765 to be highly active in treating chronic lymphocytic leukemia (CLL), achieving complete remission in one patient and partial remissions in 62% of previously untreated patients, with tolerable side effects.
Scientists have discovered a protein involved in drug resistance in breast cancer, which could be targeted for new treatments. Blocking the production of this protein in human cells made them more responsive to anti-oestrogen drugs.
A U-M study found that a curcumin-based compound, FLLL32, can improve the effectiveness of head and neck cancer treatment by sensitizing resistant cells to chemotherapy. The compound decreases activation levels of STAT3, making tumor cells more susceptible to cisplatin.
Researchers identified Abcc10 as a key player in resisting certain anticancer drugs, including taxanes. Blunting its activity may help counteract resistance and make these drugs more effective, providing hope for improved treatment options.
Ionita Ghiran's novel device uses magnetic levitation and cell phone technology to diagnose malaria outside the laboratory setting. The device is inexpensive, portable, and requires only a drop of finger-prick blood, providing a solution to the lack of suitable methods for malaria diagnosis.
A recent study found that nearly 40% of virological breakthroughs in patients receiving nucleoside analogs for chronic hepatitis B were not related to antiviral drug resistance. Non-adherence to medication was identified as a common cause of reemergence.
A novel potential drug-target for colorectal cancer treatment has been identified in a brain-derived protein. Brain-derived neurotrophic factor (BDNF) is present in greater amounts in colorectal tumors and may be involved in CRC progression and resistance to drugs.
Researchers have identified several genes that may contribute to the malaria parasite's ability to evade antimalarial drugs. One of these genes, PF10_0355, was found to render drug-sensitive parasites more resistant to three standard antimalarial agents when introduced into them.
A new drug, DCC-2036, has shown potential in treating leukemia patients who have developed resistance to standard treatment. The study found that the drug was effective against human leukemia cells and prolonged survival in a mouse model of CML.
Researchers at UMMS have developed a novel technique called EMPIRIC to produce all possible individual mutations and analyze their impact on cells. This approach enables the systematic screening of viral genomes for likelihood to develop drug resistance.
A systematic review and pooled analysis found that low-frequency HIV-1 drug resistance mutations are associated with a 2.3 times increased risk of virologic failure in treatment-naive adults, particularly those with NNRTI-resistant minority variants.
The Rheos System, a device that regulates blood pressure like a pacemaker regulates heart rhythm, helped lower blood pressure by 33 points. This substantial drop could require up to five additional drugs to control difficult-to-treat hypertension in patients with resistant hypertension.
Researchers discovered that ionizing radiation drives overexpression and activity of MET through the ATM and NF-κB signaling pathways, making some tumor cells resistant to radiation. Inhibiting MET counteracted this increased invasiveness, promoting apoptosis in tumor cells and enhancing the effect of radiation.
Rapid resistance to novel antiviral therapy develops in response to direct antiviral drugs for hepatitis C virus (HCV) treatment. New HCV treatments face resistance concerns, experts advise careful prescription and monitoring to minimize rapid development. NS3-protease and NS5A inhibitors block essential enzymes for HCV replication.
Researchers have identified a promising new approach to treating alveolar rhabdomyosarcoma by targeting the Igf1r and Her2 pathways. This method has shown promise in preventing resistance to current treatments, with significant increases in tumor cell killing when combining inhibitors.
A new treatment approach targeting CML stem cells is being tested, offering a potential cure for patients resistant to Tyrosine Kinase Inhibitors. Hydroxychloroquine has shown promise in killing cancer cells undergoing autophagy, a state that allows them to survive and return after standard therapy.
Researchers found low Rho GDI-alpha protein levels in tamoxifen-resistant breast cancer tumors, predicting recurrence. MTA2 protein levels rose with declining Rho GDI-alpha, combining to predict tumor progression.
A study found that genetic mutations leading to HIV/AIDS resistance in infants may develop from maternal antiretroviral drugs via breastfeeding. The authors suggest monitoring infants exposed to breast milk with low levels of ARVs and tailoring treatment accordingly.
A third of patients with resistant hypertension were found to have 'white coat' hypertension during ambulatory monitoring. The study suggests that those with true resistant hypertension show high blood pressure at work and during the night, but their cardiovascular outcomes are better than previously thought.
Researchers at UCLA developed a 'roadmap' of complex signaling processes in cancer that could lead to new methods for diagnosing and overcoming drug resistance. The study identifies points of susceptibility that can be targeted by 'cocktail' therapies to prevent drug resistance.
Researchers found that HIV requires base excision repair proteins to integrate its DNA into the host genome, identifying novel targets for anti-HIV drugs. The study suggests that drugs targeting these cellular proteins may avoid resistance and have fewer side effects.
Researchers identified two previously unreported resistance mechanisms and found that resistance-conferring mutations can disappear after treatment is discontinued. Repeat biopsies provide critical information for guiding treatment decisions.
Researchers at UT Southwestern Medical Center discovered a brain signaling pathway that induces leptin resistance, leading to decreased satiety and increased visceral fat. Activating this pathway, known as cAMP-EPAC, can induce leptin resistance in hypothalamic neurons, a critical site of leptin action.
A recent study found that transmitted drug-resistant (TDR) HIV significantly increases the likelihood of treatment failure, with patients more than three times as likely to experience virological failure. However, pre-treatment genotypic testing and use of ritonavir-boosted protease inhibitors can minimize this risk.
A Michigan State University researcher is conducting a cohort study to analyze seizures in HIV-positive patients and examine the effects of antiepileptic drugs on antiretroviral medicines. The study aims to determine whether dual treatment increases the risk of drug failure, AIDS, or death.
A new study found that protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) are equally effective as initial treatment for children with HIV, delaying switch to second-line drugs does not impact long-term outcomes. Regular monitoring of viral load is crucial to prevent resistance.
A new study has identified over 30 breast cancer gene targets involved in drug resistance to chemotherapy, including several novel genes. The findings may aid in the development of a more personalized approach to therapy and early screening for those who may become resistant to treatment.
Researchers at the University of Texas Health Science Center San Antonio found that resveratrol stimulates the expression of adiponectin, a hormone with wide-ranging benefits for obesity-related medical complications. This discovery provides important information on the development of novel therapeutic drugs for these diseases.
Researchers at The Wistar Institute found that tumor cells can adapt to BRAF inhibitors by re-routing signals through alternate pathways. To overcome resistance, targeting multiple signaling pathways simultaneously is key, with compounds in clinical development showing promise.
Researchers found that overexpression of HOXB7 gene leads to tamoxifen resistance by interacting with estrogen-activated genes and proteins, including HER2. Knocking out HOXB7 gene increased responsiveness to tamoxifen in breast cancer cells.
Recent studies reveal a rise in dual-resistance among certain influenza viruses, their increased transmission, and the limited availability of alternative treatment options. This poses significant public health concerns.
A Phase I trial indicates that ponatinib produces significant hematologic and cytogenetic responses in patients with chronic myeloid leukemia (CML) who have developed resistance to standard treatments. The drug showed strong efficacy in patients with the T315I mutation, which is resistant to current therapies.
Researchers have found that patients with BRAF-mutated melanoma develop resistance to targeted treatment PLX4032 through genetic mutations or cell surface protein overexpression, accounting for 40% of cases. The study aims to develop new therapies targeting these mechanisms.
Certain types of aggressive breast cancer cells bypass tumor suppression mechanisms due to the presence of Her2 proteins. The study found that protein Lip produced by these cells deactivates protective responses such as TGF-β and OIS, allowing them to grow uncontrolledly.
A research team has pinpointed a novel cancer gene called COT (MAP3K8) as a key player behind drug resistance in melanoma. The study provides a framework for discovering ways to tackle cancer drug resistance and identifies potential targets for new treatments.
A major study demonstrates the effectiveness of pre-exposure prophylaxis (PrEP) in reducing HIV infection risk in high-risk individuals. The iPrEx study found that PrEP reduced HIV infections by an average of 43.8% in participants who received the medication, with consistent use providing even greater protection.
Researchers found that HIV protease inhibitors block glucose transport, leading to insulin resistance. The discovery provides potential for safer antiviral drugs and better understanding of glucose transport in health and disease.
A global effort combines technologies and expertise from Canada and India to develop new classes of antimalarial drugs, targeting three key malaria targets. The program also harnesses novel technologies for slow-release medication delivery, potentially leading to a 'one pill cure' and reducing drug resistance.